Ionis Pharmaceuticals– tag –
-
Ionis’ Zanvastro (Zilganersen) Gains FDA Approval as First Disease-Modifying ASO Therapy for Alexander Disease
Fierce Pharma USA Overview Ionis Pharmaceuticals has received FDA approval for Zanvastro (zilganersen), an antisense oligonucleotide (ASO) therapy, as the first disease-modifying treatment for Alexander disease. Zanvastro operates by spe... -
Ionis ASO Therapy Zanvastro Receives First-Ever FDA Approval for Alexander Disease, Demonstrates Significant Stabilization of Walking Speed
Ionis Pharmaceuticals USA Overview Ionis Pharmaceuticals' antisense oligonucleotide (ASO) therapeutic, Zanvastro (zilganersen), has secured FDA approval as the first treatment for Alexander disease (AxD), a rare and progressive neurodege... -
Gilead Report Highlights RNA Therapeutic Progress: GSK/Ionis HBV ASO Shows Positive Phase 3, Novartis FSHD siRNA Promising Early Data
The Bio Report USA Overview A Gilead report underscores significant advancements in RNA therapeutic clinical trials, with GSK/Ionis's beoprovirsen, an ASO targeting HBV, demonstrating positive Phase 3 results. Novartis's siRNA therapy, D... -
2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era
MiraScope Unknown Overview The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceut... -
Arrowhead’s Plozasiran Achieves Up to 81% Triglyceride Reduction in Severe Hypertriglyceridemia Phase 3, Pressuring Ionis
Fierce Biotech USA Overview Arrowhead Pharmaceuticals has reported robust Phase 3 SHASTA-3 and SHASTA-4 trial data for its siRNA therapeutic, plozasiran, in patients with severe hypertriglyceridemia (sHTG), putting pressure on competitor... -
Ionis Enters Global Licensing Deal with Recordati for Alexander Disease ASO Zilganersen: Secures $30M Upfront Payment to Accelerate International Expansion
Rare Disease Report USA Overview Ionis Pharmaceuticals has entered a global licensing agreement with Recordati for zilganersen, an antisense oligonucleotide (ASO) for Alexander disease, covering territories outside the U.S. Ionis will re... -
Ionis’ ASO Therapy Zilganersen Awaits FDA Approval for Alexander Disease: Achieves Primary Endpoints and Granted Priority Review
BioXconomy USA Overview Ionis Pharmaceuticals' antisense oligonucleotide (ASO), zilganersen, is awaiting FDA approval for the ultra-rare neurological disorder, Alexander disease. The pivotal Phase 1-3 trial (NCT04849741) met its primary ... -
FDA Approves Expanded Indication for Ionis’ ASO Tryngolza in Severe Hypertriglyceridemia, Achieving <500 mg/dL TG Levels in 86% of Patients
Fierce Pharma USA Overview The FDA has approved an expanded indication for Ionis Pharmaceuticals’ antisense oligonucleotide (ASO) Tryngolza (olezarsen) for severe hypertriglyceridemia. Clinical trials demonstrated remarkable efficacy, wi... -
Ionis Forges $30M Ex-US Rare Disease Pact with Recordati, Accelerating Global ASO Reach
Fierce Biotech USA Overview Ionis Pharmaceuticals has secured a $30 million upfront payment from Recordati, granting the Italian firm exclusive ex-US development and commercialization rights for specific rare disease therapies. This stra...
1